Streetbeat News

Analyst Ratings

EXR

NSA

KeyBanc Capital Markets' analyst Todd Thomas has downgraded National Storage Affiliates Trust (NSA) from Overweight to Sector Weight, while maintaining an Overweight rating on Extra Space Storage Inc (EXR) and raising its price target to $178. The self-storage REITs market is expected to stabilize, with EXR planning to collapse the Life Storage brand and potential acquisition activity ahead.

Portfolio Pulse from Priya Nigam

September 09, 2024 | 3:53 pm

NVO

Cantor Fitzgerald has reiterated its Overweight rating on Novo Nordisk, maintaining a price target of $160.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:50 pm

SABS

Chardan Capital analyst Keay Nakae has reiterated a Buy rating for SAB Biotherapeutics (NASDAQ:SABS) and maintained a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:50 pm

MRNS

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:49 pm

LLY

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Eli Lilly (NYSE:LLY) and maintained a price target of $885.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:47 pm

JAZZ

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Jazz Pharmaceuticals, maintaining a price target of $140.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:43 pm

GPCR

Cantor Fitzgerald has reiterated its Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:41 pm

GILD

Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Gilead Sciences (NASDAQ:GILD) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:38 pm

WVE

Wave Life Sciences shares rose after JP Morgan initiated coverage with an Overweight rating and a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:37 pm

DNLI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics, maintaining a $35 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:36 pm